Stephan Stilgenbauer
Elite in Prolymphocytic Leukemia

Stephan Stilgenbauer

Albert Einstein Allee 23, 
Ulm, BW, DE 
Elite in Prolymphocytic Leukemia
Albert Einstein Allee 23, 
Ulm, BW, DE 
OverviewLocationsClinical Research

Overview

Stephan Stilgenbauer practices in Ulm, Germany. Mr. Stilgenbauer is rated as an Elite expert by MediFind in the treatment of Prolymphocytic Leukemia. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 384 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Prolymphocytic Leukemia.

Gender
Male

Locations

Albert Einstein Allee 23, Ulm, BW 89081, Germany
Other Locations
Kirrberger Str. 100, Homburg, SL 66421, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
View 1 Less Clinical Trial

384 Total Publications

CLL to Richter syndrome: Integrating network strategies with experiments elucidating disease drivers and personalized therapies.
CLL to Richter syndrome: Integrating network strategies with experiments elucidating disease drivers and personalized therapies.
Journal: Science advances
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stilgenbauer's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile